Table 2.
Clinical trials on CRISPR/Cas-mediated cancer therapy (https://www.clinicaltrials.gov).
| Study title | Status | Conditions | Interventions | Gender | Age | Phases | Clinical trial identifier |
|---|---|---|---|---|---|---|---|
| Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients with Mesothelin Positive Multiple Solid Tumors. | Recruiting | Solid Tumor | Biological: anti-mesothelin CAR-T cells | All | 18–70 | Phase 1 | NCT03545815 |
| A Study of Metastatic Gastrointestinal Cancers Treated with Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering | Recruiting | Gastrointestinal Cancer | Drug: Cyclophosphamide|Drug: Fludarabine| Biological: Tumor-Infiltrating Lymphocytes (TIL)|Drug: Aldesleukin | All | 18–70 | Phase1 and Phase 2 | NCT04426669 |
| A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial Neoplasia | Unknown status | Human Papillomavirus-Related Malignant Neoplasm | Biological: TALEN|Biological: CRISPR/Cas9 | Female | 18–50 | Phase 1 | NCT03057912 |
| Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells with the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors | Unknown status | Solid Tumor | Biological: Mesothelin-directed CAR-T cells | All | 18–70 | Phase 1 | NCT03747965 |
| A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) | Recruiting | B-cell Malignancy|Non-Hodgkin Lymphoma|B-cell Lymphoma|Adult B Cell ALL | Biological: CTX110 | All | 18< | Phase 1 | NCT04035434 |
| PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer | Completed | Esophageal Cancer | Other: PD-1 Knockout T Cells | All | 18–80 | Not Applicable | NCT03081715 |
| PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer | Completed | Metastatic Non-small Cell Lung Cancer | Drug: Cyclophosphamide|Other: PD-1 Knockout T Cells | All | 18–70 | Phase 1 | NCT02793856 |
| Stem Cells in NF1 Patients With Tumors of the Central Nervous System | Suspended | Neurofibromatosis Type 1|Tumors of the Central Nervous System | Diagnostic Test: Collection of Stem Cells | All | Child, Adult, Older Adult | NCT03332030 | |
| A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) | Recruiting | T Cell Lymphoma | Biological: CTX130 | All | 18< | Phase 1 | NCT04502446 |
| First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors | Terminated | Neoplasms, Pancreatic | Drug: GSK3145095|Drug: Pembrolizumab | All | 18< | Phase 2 | NCT03681951 |
| Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer | Recruiting | Ovarian Cancer | Other: Biospecimen Collection|Other: Laboratory Biomarker Analysis|Device: Lavage|Other: Pap Smear | Female | 18< | Not Applicable | NCT03606486 |
| TGF²R-KO CAR-EGFR T Cells in Previously Treated Advanced EGFR-positive Solid Tumors | Recruiting | Solid Tumor| EGFR Overexpression | Biological: TGF²R-KO CAR-EGFR T Cells | All | 18–75 | Phase 1 | NCT04976218 |
| PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer | Withdrawn | Hormone Refractory Prostate Cancer | Biological: PD-1 Knockout T Cells|Drug: Cyclophosphamide|Drug: IL-2 | Male | 45–85 | NCT02867345 | |
| PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer | Withdrawn | Invasive Bladder Cancer Stage IV | Biological: PD-1 Knockout T Cells|Drug: Cyclophosphamide|Drug: IL-2 | All | 18–75 | Phase 1 | NCT02863913 |
| CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19 + Leukemia or Lymphoma. | Recruiting | Leukemia Lymphocytic Acute (ALL) in Relapse|Leukemia Lymphocytic Acute (All) Refractory|Lymphoma, B-Cell|CD19 Positive | Genetic: XYF19 CAR-T cell|Drug: Cyclophosphamide|Drug: Fludarabine | All | 18–55 | Phase 1 | NCT04037566 |
| Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5 + Hematopoietic Malignancies | Not yet recruiting | CD5+ Relapsed/Refractory Hematopoietic Malignancies|Chronic Lymphocytic Leukemia (CLL)|Mantle Cell Lymphoma (MCL)|Diffuse Large B-cell Lymphoma (DLBCL)|Follicular Lymphoma (FL)|Peripheral T-cell Lymphomas (PTCL) | Biological: CT125A cells|Drug: Cyclophosphamide, fludarabine | All | 18–70 | Early Phase 1 | NCT04767308 |
| A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma | Recruiting | Multiple Myeloma | Biological: CTX120 | All | 18< | Phase 1 | NCT04244656 |
| Study of Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7) | Recruiting | Relapsed/Refractory T-cell Acute Lymphoid Leukemia | Biological: Cryopreserved BE CAR7 T cells (BE752TBCCLCAR7PBL) | All | 6–16 | Phase 1 | NCT05397184 |
| PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies | Unknown status | Stage IV Gastric Carcinoma|Stage IV Nasopharyngeal Carcinoma|T-Cell Lymphoma Stage IV|Stage IV Adult Hodgkin Lymphoma|Stage IV Diffuse Large B-Cell Lymphoma | Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Interleukin-2 | All | 18–75 | Phase 1|Phase 2 | NCT03044743 |
| Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia | Recruiting | Acute Myeloid Leukemia | Genetic: Arm 1: NTLA-5001|Genetic: Arm 2: NTLA-5001 | All | 18< | Phase 1|Phase 2 | NCT05066165 |
| A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma | Unknown status | B Cell Leukemia|B Cell Lymphoma | Biological: UCART019 | All | 12–75 | Phase 1|Phase 2 | NCT03166878 |
| A Long-term Follow-up Study of Patients Who Received VOR33 | Recruiting | Leukemia, Myeloid, Acute | Genetic: VOR33 | All | Child, Adult, Older Adult | NCT05309733 | |
| NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | Terminated | Multiple Myeloma |Melanoma| Synovial Sarcoma |Myxoid/Round Cell Liposarcoma | Biological: NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1| Drug: Cyclophosphamide|Drug: Fludarabine|Device: NY-ESO-1 expression testing | All | 18< | Phase 1 | NCT03399448 |
| A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC) | Recruiting | Renal Cell Carcinoma | Biological: CTX130 | All | 18< | Phase 1 | NCT04438083 |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma | Recruiting | Lymphoma | Genetic: CB-010|Drug: Cyclophosphamide|Drug: Fludarabine | All | 18< | Phase 1 | NCT04637763 |
| Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19 + Leukemia and Lymphoma | Withdrawn | Acute Lymphoblastic Leukemia |Chronic Lymphocytic Leukemia| Non-Hodgkin Lymphoma | Biological: PACE CART19 | All | 18< | Phase 1 | NCT05037669 |
| TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukemia (B-ALL) | Recruiting | B Acute Lymphoblastic Leukemia | Drug: PBLTT52CAR19 | All | 6 Months to 18 Years | Phase 1 | NCT04557436 |
| A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma | Unknown status | B Cell Leukemia Cell Lymphoma | Biological: Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells | All | 12–70 | Phase 1|Phase 2 | NCT03398967 |
| TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma. | Unknown status | Advanced Hepatocellular Carcinoma | Procedure: Transcatheter arterial chemoembolization Biological: PD-1 knockout engineered T cells | All | 18–70 | Phase 1 | NCT04417764 |
| PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma. | Withdrawn | Metastatic Renal Cell Carcinoma | Biological: PD-1 Knockout T Cells Drug: Cyclophosphamide Drug: IL-2 | All | 18–75 | Phase 1 | NCT02867332 |